Rhenium-186 has a half-life (t1/2 = 3.72 days) and emission of both gamma and beta particles that make it very attractive for use as a theranostic agent in targeted radionuclide therapy. 186Re can be readily prepared by the 185Re(n,γ)186Re reac-tion1. However, that reaction results in low specific activity, severely limiting the use of reactor produced 186Re in radiopharmaceuticals. It has previously been shown that high specific activity 186Re can be produced by cyclotron irradiations of 186W with protons and deuterons2,3. In this investigation we evaluated the 186W(d,2n)186Re reaction using thick target irradiations at higher incident deuteron energies and beam currents than previously reported. We elected not to use copper or aluminum fo...
Excitation functions and thin-target yields for the 181-186gRe radionuclides were measured by the st...
The 186gRe radionuclide is a ß-,¿ emitter that, thanks to its suitable nuclear properties (t1/2 = 90...
Patients with primary breast, prostate and lung cancer have a high frequency of bone metastases, ran...
Rhenium-186 has a half-life (t1/2 = 3.72 days) and emission of both gamma and beta particles that ma...
Introduction Rhenium-186 (t1/2 = 3.72 d) is very attractive for use as a theranostic agent in target...
Introduction Radioisotopes play an important role in nuclear medicine and represent powerful tools f...
Since its discovery in 1896, radioactivity has been used in various application areas of physics. In...
The goal of this research project was to investigate the feasibility of Rhenium-186 (186Re) as an is...
The 186gRe can be produced in carrier-added (CA) form by (n,y) reaction on enriched 185Re target in ...
Excitation functions, thin- and thick-target yields for the 181 12186gRe and 187Wradionuclideswereme...
Excitation functions, thin- and thick-target yields for the 181-186gRe and 187W radionuclides were m...
Very high specific activity (AS) 186gRe could be produced by either proton or deuteron cyclotron irr...
Excitation functions and thin-target yields for the 181 12186gRe radionuclides have been measured by...
Excitation functions, thin- and thick-target yields (tty and TTY) for the 181-186Re radionuclides ha...
Very high specific activity(AS) 186gRe could be produced by either proton or deuteron cyclotron irra...
Excitation functions and thin-target yields for the 181-186gRe radionuclides were measured by the st...
The 186gRe radionuclide is a ß-,¿ emitter that, thanks to its suitable nuclear properties (t1/2 = 90...
Patients with primary breast, prostate and lung cancer have a high frequency of bone metastases, ran...
Rhenium-186 has a half-life (t1/2 = 3.72 days) and emission of both gamma and beta particles that ma...
Introduction Rhenium-186 (t1/2 = 3.72 d) is very attractive for use as a theranostic agent in target...
Introduction Radioisotopes play an important role in nuclear medicine and represent powerful tools f...
Since its discovery in 1896, radioactivity has been used in various application areas of physics. In...
The goal of this research project was to investigate the feasibility of Rhenium-186 (186Re) as an is...
The 186gRe can be produced in carrier-added (CA) form by (n,y) reaction on enriched 185Re target in ...
Excitation functions, thin- and thick-target yields for the 181 12186gRe and 187Wradionuclideswereme...
Excitation functions, thin- and thick-target yields for the 181-186gRe and 187W radionuclides were m...
Very high specific activity (AS) 186gRe could be produced by either proton or deuteron cyclotron irr...
Excitation functions and thin-target yields for the 181 12186gRe radionuclides have been measured by...
Excitation functions, thin- and thick-target yields (tty and TTY) for the 181-186Re radionuclides ha...
Very high specific activity(AS) 186gRe could be produced by either proton or deuteron cyclotron irra...
Excitation functions and thin-target yields for the 181-186gRe radionuclides were measured by the st...
The 186gRe radionuclide is a ß-,¿ emitter that, thanks to its suitable nuclear properties (t1/2 = 90...
Patients with primary breast, prostate and lung cancer have a high frequency of bone metastases, ran...